HSulf-1 deficiency dictates a metabolic reprograming of glycolysis and TCA cycle in ovarian cancer

Oncotarget

Volumn 6, Issue 32, 2015, Pages 33705-33719

  Mondal, Susmita ^a   Roy, Debarshi ^a   Camacho Pereira, Juliana ^a,e   Khurana, Ashwani ^a   Chini, Eduardo ^a   Yang, Lifeng ^b   Baddour, Joelle ^b   Stilles, Katherine ^b   Padmabandu, Seth ^b   Leung, Sam ^c   Kalloger, Steve ^c   Gilks, Blake ^c   Lowe, Val ^a   Dierks, Thomas ^d   Hammond, Edward ^f   Dredge, Keith ^f   Nagrath, Deepak ^b   Shridhar, Viji ^a  

^a Mayo Clinic College of Medicine   (United States)

^b Rice University   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d BIELEFELD UNIVERSITY   (Germany)

^e FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^f Progen Pharmaceuticals Limited   (Australia)

Author keywords

C Myc; HB EGF; HSulf 1; Ovarian cancer; PG545; Warburg effect

Indexed keywords

ANTINEOPLASTIC AGENT; GLYCOLYTIC ENZYME; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; MYC PROTEIN; PG 545; PYRUVATE DEHYDROGENASE; UNCLASSIFIED DRUG; SULF1 PROTEIN, HUMAN; SULFOTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CITRIC ACID CYCLE; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOWN REGULATION; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; GENE; GENE EXPRESSION; GENE LOSS; GENE SILENCING; GLUCOSE TRANSPORT; GLUT1 GENE; GLYCOLYSIS; HKII GENE; HSULF 1 GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LDHA GENE; MOUSE; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CANCER; OXYGEN CONSUMPTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHENOTYPE; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; UPREGULATION; ANIMAL; CELL PROLIFERATION; DEFICIENCY; ENZYMOLOGY; GENETICS; KNOCKOUT MOUSE; METABOLISM; MICROARRAY ANALYSIS; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CITRIC ACID CYCLE; FEMALE; GLYCOLYSIS; HUMANS; MICE; MICE, KNOCKOUT; MICROARRAY ANALYSIS; OVARIAN NEOPLASMS; SIGNAL TRANSDUCTION; SULFOTRANSFERASES;

EID: 84946010452     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5605     Document Type: Article

References (41)

1. De Luca A, Maiello MR, D'Alessio A, Pergameno M and Normanno N. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets. 2012; 16 Suppl 2:S17-27.
2. Levine AJ and Puzio-Kuter AM. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science. 2010; 330:1340-1344.
3. Jones RG and Thompson CB. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev. 2009; 23:537-548.
4. Jastrebova N, Vanwildemeersch M, Lindahl U and Spillmann D. Heparan sulfate domain organization and sulfation modulate FGF-induced cell signaling. J Biol Chem. 2010; 285:26842-26851.
5. Robinson CJ, Mulloy B, Gallagher JT and Stringer SE. VEGF(165)-binding sites within heparan sulfate encompass two highly sulfated domains and can be liberated by K5 lyase. Journal of Biological Chemistry. 2006; 281:1731-1740.
6. Lai J, Chien J, Staub J, Avula R, Greene EL, Matthews TA, Smith DI, Kaufmann SH, Roberts LR and Shridhar V. Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer. J Biol Chem. 2003; 278:23107-23117.
7. Mummery RS and Rider CC. Characterization of the heparin-binding properties of IL-6. J Immunol. 2000; 165:5671-5679.
8. Pichert A, Samsonov SA, Theisgen S, Thomas L, Baumann L, Schiller J, Beck-Sickinger AG, Huster D and Pisabarro MT. Characterization of the interaction of interleukin-8 with hyaluronan, chondroitin sulfate, dermatan sulfate and their sulfated derivatives by spectroscopy and molecular modeling. Glycobiology. 2012; 22:134-145.
9. Esko JD and Lindahl U. Molecular diversity of heparan sulfate. J Clin Invest. 2001; 108:169-173.
10. Liu P, Khurana A, Rattan R, He X, Kalloger S, Dowdy S, Gilks B and Shridhar V. Regulation of HSulf-1 expression by variant hepatic nuclear factor 1 in ovarian cancer. Cancer Res. 2009; 69:4843-4850.
11. Lai JP, Chien J, Strome SE, Staub J, Montoya DP, Greene EL, Smith DI, Roberts LR and Shridhar V. HSulf-1 modulates HGF-mediated tumor cell invasion and signaling in head and neck squamous carcinoma. Oncogene. 2004; 23:1439-1447.
12. Khurana A, Beleford D, He X, Chien J and Shridhar V. Role of heparan sulfatases in ovarian and breast cancer. Am J Cancer Res. 2013; 3:34-45.
13. Narita K, Staub J, Chien J, Meyer K, Bauer M, Friedl A, Ramakrishnan S and Shridhar V. HSulf-1 inhibits angiogenesis and tumorigenesis in vivo. Cancer Res. 2006; 66:6025-6032.
14. Narita K, Chien J, Mullany SA, Staub J, Qian X, Lingle WL and Shridhar V. Loss of HSulf-1 expression enhances autocrine signaling mediated by amphiregulin in breast cancer. J Biol Chem. 2007; 282:14413-14420.
15. Khurana A, Liu P, Mellone P, Lorenzon L, Vincenzi B, Datta K, Yang B, Linhardt RJ, Lingle W, Chien J, Baldi A and Shridhar V. HSulf-1 modulates FGF2-and hypoxia-mediated migration and invasion of breast cancer cells. Cancer Res. 2011; 71:2152-2161.
16. He X, Khurana A, Roy D, Kaufmann S and Shridhar V. Loss of HSulf-1 expression enhances tumorigenicity by inhibiting Bim expression in ovarian cancer. Int J Cancer. 2014; 135:1783-1789.
17. Liu L, Ding F, Chen J, Wang B and Liu Z. hSulf-1 inhibits cell proliferation and migration and promotes apoptosis by suppressing stat3 signaling in hepatocellular carcinoma. Oncol Lett. 2014; 7:963-969.
18. Xu G, Ji W, Su Y, Xu Y, Yan Y, Shen S, Li X, Sun B, Qian H, Chen L, Fu X, Wu M and Su C. Sulfatase 1 (hSulf-1) reverses basic fibroblast growth factor-stimulated signaling and inhibits growth of hepatocellular carcinoma in animal model. Oncotarget. 2014; 5:5029-5039.
19. Zhang H, Newman DR and Sannes PL. HSULF-1 inhibits ERK and AKT signaling and decreases cell viability in vitro in human lung epithelial cells. Respir Res. 2012; 13:69.
20. Ma HY, Zhang F, Li J, Mo ML, Chen Z, Liu L, Zhou HM and Sheng Q. HSulf-1 suppresses cell growth and downregulates Hedgehog signaling in human gastric cancer cells. Oncol Lett. 2011; 2:1291-1295.
21. Roy D, Mondal S, Wang C, He X, Khurana A, Giri S, Hoffmann R, Jung DB, Kim SH, Chini EN, Periera JC, Folmes CD, Mariani A, Dowdy SC, Bakkum-Gamez JN, Riska SM, et al. Loss of HSulf-1 promotes altered lipid metabolism in ovarian cancer. Cancer Metab. 2014; 2:13.
22. WinterhoffB, Freyer L, Hammond E, Giri S, Mondal S, Roy D, Teoman A, Mullany SA, Hoffmann R, von Bismarck A, Chien J, Block MS, Millward M, Bampton D, Dredge K and Shridhar V. PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples. Eur J Cancer. 2015; 51:879-892.
23. Sugden MC and Holness MJ. Recent advances in mechanisms regulating glucose oxidation at the level of the pyruvate dehydrogenase complex by PDKs. Am J Physiol Endocrinol Metab. 2003; 284:E855-862.
24. Wigfield SM, Winter SC, Giatromanolaki A, Taylor J, Koukourakis ML and Harris AL. PDK-1 regulates lactate production in hypoxia and is associated with poor prognosis in head and neck squamous cancer. Br J Cancer. 2008; 98:1975-1984.
25. Wu M, Neilson A, Swift AL, Moran R, Tamagnine J, Parslow D, Armistead S, Lemire K, Orrell J, Teich J, Chomicz S and Ferrick DA. Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells. Am J Physiol Cell Physiol. 2007; 292:C125-136.
26. Kroemer G and Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell. 2008; 13:472-482.
27. Vander Heiden MG, Cantley LC and Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009; 324:1029-1033.
28. Fantin VR, St-Pierre J and Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell. 2006; 9:425-434.
29. Zheng J. Energy metabolism of cancer: Glycolysis versus oxidative phosphorylation (Review). Oncol Lett. 2012; 4:1151-1157.
30. Capuano F, Guerrieri F and Papa S. Oxidative phosphorylation enzymes in normal and neoplastic cell growth. J Bioenerg Biomembr. 1997; 29:379-384.
31. Ward PS and Thompson CB. Signaling in control of cell growth and metabolism. Cold Spring Harb Perspect Biol. 2012; 4:a006783.
32. Miller DM, Thomas SD, Islam A, Muench D and Sedoris K. c-Myc and cancer metabolism. Clin Cancer Res. 2012; 18:5546-5553.
33. Kim J, Lee JH and Iyer VR. Global identification of Myc target genes reveals its direct role in mitochondrial biogenesis and its E-box usage in vivo. PLoS One. 2008; 3:e1798.
34. Uttamsingh S, Bao X, Nguyen KT, Bhanot M, Gong J, Chan JL, Liu F, Chu TT and Wang LH. Synergistic effect between EGF and TGF-beta1 in inducing oncogenic properties of intestinal epithelial cells. Oncogene. 2008; 27:2626-2634.
35. Zhang X, Meng J and Wang ZY. A switch role of Src in the biphasic EGF signaling of ER-negative breast cancer cells. PLoS One. 2012; 7:e41613.
36. Fan Y, Dickman KG and Zong WX. Akt and c-Myc differentially activate cellular metabolic programs and prime cells to bioenergetic inhibition. J Biol Chem. 2010; 285:7324-7333.
37. Tai S, Sun Y, Squires JM, Zhang H, Oh WK, Liang CZ and Huang J. PC3 is a cell line characteristic of prostatic small cell carcinoma. Prostate. 2011; 71:1668-1679.
38. Lamanna WC, Baldwin RJ, Padva M, Kalus I, Ten Dam G, van Kuppevelt TH, Gallagher JT, von Figura K, Dierks T and Merry CL. Heparan sulfate 6-O-endosulfatases: discrete in vivo activities and functional co-operativity. Biochem J. 2006; 400:63-73.
39. Mondal S, Mandal C, Sangwan R and Chandra S. Withanolide D induces apoptosis in leukemia by targeting the activation of neutral sphingomyelinase-ceramide cascade mediated by synergistic activation of c-Jun N-terminal kinase and p38 mitogen-activated protein kinase. Mol Cancer. 2010; 9:239.
40. Yang L, Moss T, Mangala LS, Marini J, Zhao H, Wahlig S, Armaiz-Pena G, Jiang D, Achreja A, Win J, Roopaimoole R, Rodriguez-Aguayo C, Mercado-Uribe I, LopezBerestein G, Liu J, Tsukamoto T, et al. Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Mol Syst Biol. 2014; 10:728.
41. Nagrath D, Caneba C, Karedath T and Bellance N. Metabolomics for mitochondrial and cancer studies. Biochim Biophys Acta. 2011; 1807:650-663.